Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension
ConclusionsEfficacy and safety for romosozumab-to-denosumab were similar between Japanese women and the overall population. The sequence of romosozumab to rebuild the skeletal foundation before transitioning to antiresorptive treatment with denosumab is a promising regimen for Japanese postmenopausal women with osteoporosis at high risk of fracture.
Source: Archives of Orthopaedic and Trauma Surgery - Category: Orthopaedics Source Type: research
More News: Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Heart | Japan Health | Orthopaedics | Osteoporosis | Statistics | Study | Women | Xgeva